Navigation Links
Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
Date:8/31/2007

SAN DIEGO, Aug. 31 /PRNewswire-FirstCall/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) announced today that the company is scheduled to present at the NewsMakers in the Biotech Industry Conference on September 6, 2007 at 10:00 a.m. Eastern Time (7:00 a.m. Pacific Time) at the Millennium Broadway Hotel in New York City. Jack Lief, Arena's President and Chief Executive Officer, is scheduled to provide a corporate overview of the company and its clinical development and discovery programs.

A live audio webcast of the presentation will be available under the investor relations section of Arena's website at http://www.arenapharm.com. A replay of the presentation will be available for 30 days following the event. Please connect to Arena's website several minutes prior to the start of the webcast to ensure adequate time for any software download that may be necessary.

About Arena Pharmaceuticals

Arena is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing oral drugs in four major therapeutic areas: cardiovascular, central nervous system, inflammatory, and metabolic diseases. Arena's most advanced product candidate, lorcaserin, is being investigated in a Phase 3 clinical trial program for the treatment of obesity. Arena's broad pipeline of novel compounds targeting G protein-coupled receptors, an important class of validated drug targets, includes compounds being evaluated independently and with its partners, Merck & Co., Inc. and Ortho-McNeil Pharmaceutical, Inc.

Arena Pharmaceuticals(R) and Arena(R) are registered service marks of the company. "APD" is an abbreviation for Arena Pharmaceuticals Development.

Forward-Looking Statements

Certain statements in this press release are forward-looking statements that involve a number of risks and uncertainties. Such forward-looking statements include statements about Arena's strategy, preclinical and internal and partnered clinical programs, and ability to develop compounds and commercialize drugs. For such statements, Arena claims the protection of the Private Securities Litigation Reform Act of 1995. Actual events or results may differ materially from Arena's expectations. Factors that could cause actual results to differ materially from the forward-looking statements include, but are not limited to, Arena's planned clinical trials may not proceed at the time Arena expects or at all, the results of preclinical studies or clinical trials may not be predictive of future results, Arena's ability to partner lorcaserin, APD125, APD791 or other of its compounds or programs, the timing, success and cost of Arena's research, out-licensing endeavors and clinical trials, Arena's ability to obtain additional financing, Arena's ability to obtain and defend its patents, and the timing and receipt of payments and fees, if any, from Arena's collaborators. Additional factors that could cause actual results to differ materially from those stated or implied by Arena's forward-looking statements are disclosed in Arena's filings with the Securities and Exchange Commission. These forward-looking statements represent Arena's judgment as of the time of this release. Arena disclaims any intent or obligation to update these forward-looking statements, other than as may be required under applicable law.

Contacts: Jack Lief Mary Claire Duch

President and CEO WeissComm Partners

Media Relations

David Walsey 212.301.7228

Director, Corporate Communications

Arena Pharmaceuticals, Inc.

858.453.7200, ext. 1682


'/>"/>
SOURCE Arena Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. Supply of Radiopharmaceuticals Hampered by Attacks
2. FDA approves Watson Pharmaceuticals Oxytrol patch
3. Ranbaxy Pharmaceuticals Inc awarded the prestigious outstanding supplier award received from Wal-Mart
4. Antigenics Pharmaceuticals plans for Phase III trial of its Melanoma vaccine
5. United Kingdom Is Lagging In Novelty In The Field Of Pharmaceuticals
6. Top Pharmaceuticals Influence Doctors Prescriptions
7. More Study On Side Effects of ADHD Drug Needed: Shire Pharmaceuticals
8. Personalized Medicine and Innovative Pharmaceuticals
9. New lease of life for asthmatics by Accentia Biopharmaceuticals
10. Pravastatin Launched by Watson Pharmaceuticals
11. Tata Industries picks up stake in Indigene Pharmaceuticals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/20/2017)... ... 2017 , ... “The Angel”: a heartwarming and earnest tale of faith ... his children. “The Angel” is the creation of published author, Marjorie Lund-Fontaine, a former ... impassioned writer. , When asked of her new book, Marjorie says, “‘The Angel’ was ...
(Date:1/20/2017)... ... January 20, 2017 , ... “Journey to Christmas:” a beautiful and enchanting tale that teaches ... Kimberly Cordoves, a mother of three in Oklahoma City, and a devoted woman of faith. ... a book has been in the back of my mind for years, but actually doing ...
(Date:1/19/2017)... ... January 19, 2017 , ... Aerolib ... system for Clinical and Regulatory education for Physicians, Physician Advisors, Case managers, ... education methodology of Disease Specific Documentation Improvement. , The Aerolib Learning Management ...
(Date:1/19/2017)... ... 19, 2017 , ... LabRoots , the leading provider ... world, announces the launch of its newly redesigned website. The sleek new design ... and trending news, vital information on upcoming virtual events and webinars, all while ...
(Date:1/19/2017)... (PRWEB) , ... January 19, 2017 , ... ... technologies and development solutions for drugs, biologics and consumer health products, today announced ... Lipids,” with Gattefossé, the leader in innovative excipients and drug delivery solutions to ...
Breaking Medicine News(10 mins):
(Date:1/19/2017)... , Jan. 18, 2017  ViewRay, Inc. (Nasdaq: ... first and only clinical MRI-guided radiation therapy system, announced ... of approximately $26.1 million through a private placement ... Management led the financing and was joined by ... LLC and Kearny Venture Partners, and an additional ...
(Date:1/19/2017)... , Jan. 18, 2017 The drug ... billion by 2021 from USD 1,179.20 billion in 2016, ... Increasing prevalence of chronic diseases, increasing demand for ... factors driving the growth of this market. Whereas, self-administration ... generic drugs offer significant growth opportunities for players operating ...
(Date:1/18/2017)... 18, 2017  Aprima Medical Software, a leading ... management (PM) and revenue cycle management (RCM) solutions ... a former reseller Healthcare Data Solutions (HDS) of ... Aprima will assume full support for HDS,s customers, ... practices across 15 states. Financial terms were not ...
Breaking Medicine Technology: